MCM2 and acute myeloid leukemia: Furthermore, DNA replication licensing factor MCM2, nucleosome assembly protein 1-like 4 (NAP1L4), serine/arginine-rich splicing factor 11 (SRSF11), and DNA topoisomerase 2-alpha (TOP2A) were also inhibited after treatment with CIGB-300, although the downregulated phospho-residue was different in each AML cell line (Table 1, Table S6).